Composition for preventing or treating fracture or osteoporosis using slit-robo system

Patent metadata

Field	Value
Publication number	US-9802994-B2
Application number	US-201314408275-A
Country	US
Kind code	B2
Filing date	Jun 14, 2013
Priority date	Jun 15, 2012
Publication date	Oct 31, 2017
Grant date	Oct 31, 2017

Abstract

A pharmaceutical composition for preventing or treating a fracture or osteoporosis, includes, as an active ingredient, a gene selected from a group consisting of slit1, slit2, slit3, robo1, robo2 and vilse, or an expressed protein of the gene. A marker composition for predicting the risk of the occurrence of a fracture or osteoporosis includes the protein. A kit for predicting the risk of the occurrence of a fracture or osteoporosis includes an antibody that specifically binds to the protein. An information provision method for predicting the risk of the occurrence of a fracture or osteoporosis includes measuring the level of expression of the slit protein through an antigen-antibody binding reaction using an antibody that specifically binds to the protein. The slit3 may increase bone formation and decrease bone reabsorption in a cellular and animal model, and has a negative correlation with the incidence rate of osteoporosis.

First claim

The invention claimed is:

1. A method for treating osteoporosis, the method comprising administering a therapeutically effective amount of a peptide of a leucine-rich repeat 2 (LRR2) domain of slit3 protein to a subject requiring a treatment of said osteoporosis,
wherein the peptide of LRR2 domain has the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 17, and the coding region corresponds to nucleotide residues 2 to 391 of SEQ ID NO: 17.

2. A method for treating osteoporosis, the method comprising administering a therapeutically effective amount of a peptide of a leucine-rich repeat 2 (LRR2) domain of slit3 protein to a subject requiring a treatment of said osteoporosis,
wherein the peptide of LRR2 domain has the amino acid sequence of SEQ ID NO: 46.

Assignees

• Asan Found

Inventors

• Koh Jung-Min
• Kim Ghi Su
• Lee Seung Hun
• Lee Young-Sun
• Kim Beom-Jun

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61P19/10

  for osteoporosis · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title